User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Analytical performance and clinical utility of the INNOTEST (R) PHOSPHO-TAU((181P)) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies

Primary tabs

Vanderstichele, Hugo De Vreese, Karen Blennow, Kaj Andreasen, Niels Sindic, Christian [UCL] Ivanoiu, Adrian [UCL] Vanmechelen, Eugeen

Background: Total tau (T-tau) and beta-amyloid((1-42)) (A beta(1-42)) levels in cerebrospinal fluid (CSF) can differentiate Alzheimer's disease (AD) from normal aging or depressive pseudo-dementia. Differential diagnosis from dementia with Lewy bodies (DLB) in clinical settings is difficult. Methods: The analytical performance of the INNOTEST (R) PHOSPHO-TAU((181P)) assay was validated in terms of selectivity, sensitivity, specificity, precision, robustness, and stability. Clinical utility of the assay alone, or combined with T-tau and AP1-421 for discrimination of AD (n=94) from patients suffering from DLB (n=60) or from age-matched control subjects (CS) (n=60) was assessed in a multicenter study. Results: CSF concentrations of tau phosphorylated at threonine 181 (P-tau(181P)) in AD was significantly higher than in DLB and CS. Discriminant analysis, a classification tree, and logistic regression showed that P-tau(181P) was the most statistically significant single variable of the three biomarkers for discrimination between AD and DLB. Conclusions: P-tau(181P) quantification is a robust and reliable assay that may be useful in discriminating AD from DLB.

Document type Article de périodique (Journal article) – Article de recherche – Evaluation Studies, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't
Access type Accès restreint
Publication date 2006
Language Anglais
Journal information "Clinical Chemistry and Laboratory Medicine : Associated with FESCC and IFCC" - Vol. 44, no. 12, p. 1472-1480 (2006)
Peer reviewed yes
Publisher Walterde Gruyter GmbH & Co. KG ((Germany) Berlin)
issn 1434-6621
e-issn 1437-4331
Publication status Publié
Affiliations UCL - MD/NOPS - Département de neurologie et de psychiatrie
UCL - (SLuc) Service de neurologie
UCL - (SLuc) Centre de référence pour l'épilepsie réfractaire
MESH Subject tau Proteins - cerebrospinal fluid - metabolism ; Sensitivity and Specificity ; Reproducibility of Results ; Reagent Kits, Diagnostic - standards ; ROC Curve ; Phosphothreonine - metabolism ; Peptide Fragments - cerebrospinal fluid ; Middle Aged ; Male ; Logistic Models ; Lewy Body Disease - diagnosis ; Humans ; Female ; Enzyme-Linked Immunosorbent Assay - methods ; Discriminant Analysis ; Diagnosis, Differential ; Biological Markers - cerebrospinal fluid ; Amyloid beta-Peptides - cerebrospinal fluid ; Alzheimer Disease - diagnosis ; Aged
Keywords Alzheimer's disease ; cerebrospinal fluid ; dementia ; diagnosis ; performance ; P-tau(181P)
Links
  1. Wiltfang Jens, Esselmann Hermann, Maler Juan Manuel, Bleich Stefan, Hüther Gerald, Kornhuber Johannes, Molecular Biology of Alzheimer’s Dementia and Its Clinical Relevance to Early Diagnosis and New Therapeutic Strategies, 10.1159/000052775
  2. Buée Luc, Bussière Thierry, Buée-Scherrer Valérie, Delacourte André, Hof Patrick R., Tau protein isoforms, phosphorylation and role in neurodegenerative disorders11These authors contributed equally to this work., 10.1016/s0165-0173(00)00019-9
  3. Blennow Kaj, Hampel Harald, CSF markers for incipient Alzheimer's disease, 10.1016/s1474-4422(03)00530-1
  4. Schoonenboom N. S.M., Pijnenburg Y. A.L., Mulder C., Rosso S. M., Van Elk E. -J., Van Kamp G. J., Van Swieten J. C., Scheltens Ph., Amyloid  (1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease, 10.1212/01.wnl.0000123249.58898.e0
  5. Goedert M., Spillantini M.G., Jakes R., Rutherford D., Crowther R.A., Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease, 10.1016/0896-6273(89)90210-9
  6. Vandermeeren Marc, Mercken Marc, Vanmechelen Eugeen, Six Jan, Voorde André, Martin Jean-Jacques, Cras Patrick, Detection of Proteins in Normal and Alzheimer's Disease Cerebrospinal Fluid with a Sensitive Sandwich Enzyme-Linked Immunosorbent Assay, 10.1111/j.1471-4159.1993.tb09823.x
  7. Vanderstichele Hugo, Kerschaver Els Van, Hesse Camilla, Davidsson Pia, Buyse Marie-Ange, Andreasen Niels, Minthon Lennart, Wallin Anders, Blennow Kaj, Vanmechelen Eugeen, Standardization of measurement of β-amyloid(1-42)in cerebrospinal fluid and plasma, 10.3109/13506120009146438
  8. Vanmechelen, Neurosci Lett, 181 (2000)
  9. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E. M., Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease, 10.1212/wnl.34.7.939
  10. McKeith I.G., Galasko D., Kosaka K., Perry E.K., Dickson D.W., Hansen L.A., Salmon D.P., Lowe J., Mirra S.S., Byrne E.J., Lennox G., Quinn N.P., Edwardson J.A., Ince P.G., Bergeron C., Burns A., Miller B.L., Lovestone S., Collerton D., Jansen E.N.H., Ballard C., de Vos R.A.I., Wilcock G.K., Jellinger K.A., Perry R.H., Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop, 10.1212/wnl.47.5.1113
  11. Folstein Marshal F., Folstein Susan E., McHugh Paul R., “Mini-mental state”, 10.1016/0022-3956(75)90026-6
  12. Hulstaert F., Blennow K., Ivanoiu A., Schoonderwaldt H. C., Riemenschneider M., Deyn P. P. D., Bancher C., Cras P., Wiltfang J., Mehta P. D., Iqbal K., Pottel H., Vanmechelen E., Vanderstichele H., Improved discrimination of AD patients using  -amyloid(1-42) and tau levels in CSF, 10.1212/wnl.52.8.1555
  13. Goedert, Biochem J, 7, 301 (1994)
  14. Sjogren M, Both total and phosphorylated tau are increased in Alzheimer's disease, 10.1136/jnnp.70.5.624
  15. Olsson A., Simultaneous Measurement of  -Amyloid(1-42), Total Tau, and Phosphorylated Tau (Thr181) in Cerebrospinal Fluid by the xMAP Technology, 10.1373/clinchem.2004.039347
  16. Mollenhauer, Clin Chem Lab Med, 40, 181 (2006)
  17. Blennow Kaj, Cerebrospinal fluid protein biomarkers for Alzheimer’s disease, 10.1602/neurorx.1.2.213
  18. Hampel Harald, Buerger Katharina, Zinkowski Raymond, Teipel Stefan J., Goernitz Alexander, Andreasen Niels, Sjoegren Magnus, DeBernardis John, Kerkman Daniel, Ishiguro Koichi, Ohno Hideto, Vanmechelen Eugeen, Vanderstichele Hugo, McCulloch Cheryl, Möller Hans-Jürgen, Davies Peter, Blennow Kaj, Measurement of Phosphorylated Tau Epitopes in the Differential Diagnosisof Alzheimer Disease : A Comparative Cerebrospinal Fluid Study, 10.1001/archpsyc.61.1.95
  19. Buerger K., Ewers M., Andreasen N., Zinkowski R., Ishiguro K., Vanmechelen E., Teipel S. J., Graz C., Blennow K., Hampel H., Phosphorylated tau predicts rate of cognitive decline in MCI subjects: A comparative CSF study, 10.1212/01.wnl.0000183284.92920.f2
  20. Buerger Katharina, Zinkowski Raymond, Teipel Stefan J., Tapiola Tero, Arai Hiroyuki, Blennow Kaj, Andreasen Niels, Hofmann-Kiefer Klaus, DeBernardis John, Kerkman Daniel, McCulloch Cheryl, Kohnken Russell, Padberg Frank, Pirttilä Tuula, Schapiro Marc B., Rapoport Stanley I., Möller Hans-Jürgen, Davies Peter, Hampel Harald, Differential Diagnosis of Alzheimer Disease With Cerebrospinal Fluid Levels of Tau Protein Phosphorylated at Threonine 231, 10.1001/archneur.59.8.1267
  21. Nägga Katarina, Gottfries Johan, Blennow Kaj, Marcusson Jan, Cerebrospinal Fluid Phospho-Tau, Total Tau and β-Amyloid1–42 in the Differentiation between Alzheimer’s Disease and Vascular Dementia, 10.1159/000066023
  22. Jimenez-Jimenez F. J., Hernanz A., Medina-Acebron S., de Bustos F., Zurdo J. M., Alonso H., Puertas I., Barcenilla B., Sayed Y., Cabrera-Valdivia F., Tau protein concentrations in cerebrospinal fluid of patients with amyotrophic lateral sclerosis, 10.1111/j.1600-0404.2005.00370.x
  23. Riemenschneider M, Wagenpfeil S, Vanderstichele H, Otto M, Wiltfang J, Kretzschmar H, Vanmechelen E, Förstl H, Kurz A, Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt–Jakob disease from other dementias, 10.1038/sj.mp.4001220
  24. Lewczuk Piotr, Esselmann Hermann, Bibl Mirko, Beck Georg, Maler Juan Manuel, Otto Markus, Kornhuber Johannes, Wiltfang Jens, Tau Protein Phosphorylated at Threonine 181 in CSF as a Neurochemical Biomarker in Alzheimer's Disease: Original Data and Review of the Literature, 10.1385/jmn:23:1-2:115
  25. Maddalena, Arch Neurol, 42, 1202 (2003)
  26. Mollenhauer Brit, Cepek Lukas, Bibl Mirko, Wiltfang Jens, Schulz-Schaeffer Walter J., Ciesielczyk Barbara, Neumann Manuela, Steinacker Petra, Kretzschmar Hans A., Poser Sigrid, Trenkwalder Claudia, Otto Markus, Tau Protein, Aβ42 and S-100B Protein in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies, 10.1159/000083178
Bibliographic reference Vanderstichele, Hugo ; De Vreese, Karen ; Blennow, Kaj ; Andreasen, Niels ; Sindic, Christian ; et. al. Analytical performance and clinical utility of the INNOTEST (R) PHOSPHO-TAU((181P)) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. In: Clinical Chemistry and Laboratory Medicine : Associated with FESCC and IFCC, Vol. 44, no. 12, p. 1472-1480 (2006)
Permanent URL http://hdl.handle.net/2078.1/37855